Covid-19 Breakthrough: Protein PTX-3 Identified as Long-Term Damage Biomarker
A groundbreaking discovery has been made by researchers at the Medical University of Vienna. They found that a protein called PTX-3 could serve as a biomarker for long-term tissue damage and potential complications after Covid-19. This finding was published and announced in October 2025.
The study, which tracked post-COVID patients for up to ten months, revealed that PTX-3 levels remained significantly elevated in severely ill patients long after the acute infection had passed. This was unlike other acute phase proteins, which typically return to normal levels within weeks.
The researchers, led by the Medical University of Vienna, believe that elevated PTX-3 levels may indicate persistent repair mechanisms or remaining SARS-CoV-2 residues in the body. This discovery could pave the way for better understanding and management of Long Covid symptoms.
The potential biomarker, PTX-3, was found to be elevated in the blood of severely ill Covid-19 patients months after acute infection. This breakthrough could significantly impact the diagnosis and treatment of Long Covid, helping patients and healthcare providers alike.
